Procyanidin B3 and Its Derivatives Alleviate Neuronal Injury by Targeting G3BP1 for Ischemic Stroke Therapy

Ischemic stroke (IS) is a leading cause of mortality and disability worldwide, but effective therapeutic options are limited. In this study, a chemical proteomic strategy is employed using the active compound procyanidin B3 (PB3) as a chemical probe to identify the therapeutic targets for IS. It is discovered that the Ras GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) is a key target of PB3, which exerts a neuroprotective effect by inhibiting the degradation of stress granules and reducing apoptosis. Based on this finding, 14 PB3 derivatives are designed and synthesized, among which compound 6c exhibited potent neuroprotective activity and favorable blood-brain barrier permeability. This study not only establishes G3BP1 as a promising therapeutic target for IS but also highlights the potential of PB3 and its derivatives for the development of IS therapeutic agents.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2025-09-26
DOI
https://doi.org/10.1002/advs.202509781
Citations
2
Primary Topic
Neuroscience and Neuropharmacology Research
Type
article
Field-Weighted Citation Impact
1.82

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Procyanidin B3 and Its Derivatives Alleviate Neuronal Injury by Targeting G3BP1 for Ischemic Stroke Therapy

Heyanhao Zhang, Huanren Yan, Ming‐Tsan Lin, Subei Tan et al.
2 citations
Advanced Science
Neuroscience and Neuropharmacology Research
1.82
article

Procyanidin B3 and Its Derivatives Alleviate Neuronal Injury by Targeting G3BP1 for Ischemic Stroke Therapy

Heyanhao Zhang, Huanren Yan, Ming‐Tsan Lin, Subei Tan, Jun Chang, Jinghuan Wang, Ning Yan, Wen Zhong, Yibo Chen, Yuyu Zhang, Xinhua Liu
article en
2 citations

Abstract

Ischemic stroke (IS) is a leading cause of mortality and disability worldwide, but effective therapeutic options are limited. In this study, a chemical proteomic strategy is employed using the active compound procyanidin B3 (PB3) as a chemical probe to identify the therapeutic targets for IS. It is discovered that the Ras GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) is a key target of PB3, which exerts a neuroprotective effect by inhibiting the degradation of stress granules and reducing apoptosis. Based on this finding, 14 PB3 derivatives are designed and synthesized, among which compound 6c exhibited potent neuroprotective activity and favorable blood-brain barrier permeability. This study not only establishes G3BP1 as a promising therapeutic target for IS but also highlights the potential of PB3 and its derivatives for the development of IS therapeutic agents.

Advanced ScienceVol. 12(45)
Shanghai University of Traditional Chinese Medicine (CN)
Science and Technology Commission of Shanghai Municipality
Openalex Percentile: Top 13%
Neuroscience and Neuropharmacology Research
1.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Procyanidin B3 and Its Derivatives Alleviate Neuronal Injury by Targeting G3BP1 for Ischemic Stroke Therapy — Heyanhao Zhang, Huanren Yan, et al. · Advanced Science (2025) | TGRS Research Map | TGRS